The purpose of this study was to evaluate the effect of alpha-IFN maintenance treatment after autologous stem cell transplantation (ASCT) for multiple myeloma in a retrospective registry analysis. 473 patients with multiple myeloma who received IFN maintenance treatment ASCT were compared with 419 patients who did not receive IFN-treatment. Patients who were evaluable for response and in complete or partial remission at 6 months after ASCT were eligible, after excluding patients with graft failure. Cox proportional hazards assumptions were checked and handled by stratification. The prognostic variables unevenly distributed between the two groups were statistically corrected for in the Cox analysis. 391 patients reached complete remission (CR) after ASCT (203 in the IFN group and 188 in the no-IFN group) and 501 were in partial remission (PR, IFN 270, no-IFN was the cause of death in 94% of the IFN-treated patients and in 83% of the no-IFN group (P = NS). Thus, IFN maintenance treatment after ASCT was associated with better OS and PFS. Treatment seemed to be most beneficial in patients who did not achieve CR. The difference in median survival was as long as 2.5 years, and although part of this difference is attributable to differences in other prognostic factors, it might justify possible differences in quality-of-life due to adverse effects of interferon treatment. Bone Marrow Transplantation (2001) 27, 511-515.
Multiple myeloma (MM) is a malignant hematological disease most common in the elderly. Although usually sensitive to chemotherapy with cytotoxic drugs, such treatment rarely induces complete remission and never cure, and after various periods of time most patients succumb due to disease progression. For younger patients, allogeneic bone marrow transplantation may induce long-term remissions and maybe cure in some patients, but this method has hitherto been hampered by the high rate of fatal transplantrelated toxicity. 1 Currently, the best treatment option for patients under the age of 60 to 65 years is high-dose cytotoxic treatment with autologous hematopoietic stem cell transplantation (ASCT), which has been demonstrated to be superior to conventional combination chemotherapy for this patient category. 2 Even so, in spite of long-term responses and improvements in long-term survival, all patients will eventually suffer myeloma progression or relapse, and cure of disease seems to occur rarely, if ever.
The anti-myeloma activity of alpha-interferon (␣-IFN) was originally demonstrated by Mellstedt et al in 1979, 3 and has subsequently been used in several studies both as additional and maintenance treatment after induction chemotherapy. [4] [5] [6] [7] [8] [9] [10] In some of these studies the results have been promising, which has lead to further attempts to use ␣-IFN to control minimal residual disease in the transplant setting. In a recent study, ␣-IFN was demonstrated to increase CR rates after allogeneic stem cell transplantation. 11 In a few uncontrolled studies there have been indications of ␣-IFN inducing a prolongation of time to disease progression, as well as time of survival after ASCT. [12] [13] [14] To date, only one randomized study investigating the effect of ␣-IFN after ASCT has been published: 15 Cunningham et al studied 85 patients who received an ASCT as part of their first-line treatment, and were randomly assigned to ␣-IFN maintenance treatment or not. At 4 years after ASCT, overall survival (OS) and progression-free survival (PFS) were significantly better in the ␣-IFN-treated group of patients. However, this beneficial effect disappeared with additional follow-up, and at 77 months no significant difference between the two groups could be detected. The authors conclude that since the study was small, further studies are needed to identify the role for ␣-IFN after highdose treatment.
Here, we present the results of a retrospective registry study of a large number of MM patients who received highdose treatment (HDT) and ASCT. Statistical control methods have been used in order to make the treated and untreated group as comparable as possible, and to control for bias with respect to the initiation of ␣-IFN treatment. The study demonstrates a significant prolongation of OS and PFS in the ␣-IFN treated group.
Patients and methods
Four hundred and seventy-three patients with MM who received ␣-IFN maintenance treatment after high-dose chemo/radiotherapy and ASCT were included in the study. These patients comprised all patients reported to the EBMT Myeloma Registry who fulfilled the inclusion criteria, ie, who had engrafted after a single autograft procedure, and were evaluable for response and in complete or partial remission at 6 months after transplantation. The ␣-IFNtreated group was retrospectively compared with a control group of patients fulfilling the same inclusion criteria, but who received no maintenance ␣-IFN therapy. The patients were transplanted during the years 1988 to 1998, and the most recent update was undertaken in May 1999. Median follow-up was 23 months (range, 0-100) from a time point 6 months after transplantation. Patient characteristics are shown in Table 1 . The factors unevenly distributed between the two groups were statistically corrected for in the survival analysis. Three hundred and ninety-one patients reached complete remission (CR) after ASCT (203 in the IFN group and 188 in the no-IFN group) and 501 were in partial remission (PR: IFN, 270; no-IFN, 231). 
Definitions
Complete remission (CR) was defined as absence of detectable monoclonal immunoglobulin in serum or abnormal light chains in urine on conventional electrophoresis or immunofixation and the absence of myeloma cells in bone marrow on conventional cytologic analysis; partial remission (PR), a decrease in the serum M-component that was more than 50% of the pretreatment value, a decrease in urinary light-chain excretion to less than 0.2 g per 24 h, or both, combined with a hemoglobin level of more than 90 g per liter, a serum albumin value of more than 30 g per liter, and a serum calcium level of less than 2.61 mmol/liter; relapse (from CR), reappearance of detectable paraprotein and/or recurrence of bone marrow infiltration; progression, 50% increase in measurable paraprotein above 'plateau' on two samples 4 weeks apart and/or an increase in bone marrow plasma cells on two samples 4 weeks apart. A patient was defined as having graft failure and not included in the analysis if the neutrophil count had not reached 0.5 ϫ 10 9 /1 at day 60 and/or the platelet count had not reached 50 ϫ 10 9 /1 at day 180 post ASCT.
Statistics
The 892 patients included in the study represent all patients transplanted from 1988 to 1998 who were completely reported to the EBMT Myeloma Registry in May 1999 and who fulfilled the inclusion criteria of the study.
All analyses have been computed using the statistical program SAS System for Windows, version 6.12. Comparisons of frequencies between groups were performed using the chi-square test. Median values were compared by Wilcoxon's rank-sum test. Survival was analyzed with the Cox proportional hazard model. The assumptions were checked and handled by stratification: patient sex and response at the time of inclusion were the stratification variables for survival, while for progression-free survival it was response at the time of inclusion. Other variables previously known to be of prognostic influence on survival were also included in the model, namely age, time between diagnosis and transplant, stage at diagnosis, number of lines of treatment, the use of a TBI/non-TBI pretransplant conditioning regimen and (only for progression-free survival) patient sex. Other potential prognostic factors, such as beta-2-microglobulin at diagnosis, CRP, LDH and karyotypic abnormalities, were not included because registry data were not available or available in only a small number of patients. Survival curves were made using the KaplanMeier product limit method. Survival time was calculated from the time point of patient inclusion 6 months after ASCT.
Results
Overall survival (OS) was significantly better in the IFNgroup compared to the patients who did not get IFN (median OS, 78 vs 47 months, P = 0.007; Figure 1a ). The survival difference was most obvious in the patients who were in PR after ASCT (median survival 97 months for the IFN-group vs 46 months for the no-IFN-group, P = 0.03; Figure 1b ), while it was of borderline statistical significance in the CR patients (64 vs 51 months, P = 0.1; Figure 1c ). Progression-free survival (PFS) for all patients analyzed was also significantly better in the IFN-treated group (median 29 vs 20 months, P = 0.006; Figure 2a ). For CR patients, there was no significant difference in relapse-free survival between the two groups (median for IFN, 29 months vs no-IFN, 22 months, P = 0.6; Figure 2b ). For PR patients, PFS was superior in the IFN arm (median 31 vs 18 months, P = 0.003; Figure 2c ). The multivariate analysis is presented in Table 2 . Progressive myeloma was the cause of death in 79 of 84 deaths of the IFN-treated patients and in 104 of 125 patients of the no-IFN group, respectively (P = 0.25).
Discussion
This retrospective case-matched registry study of ␣-IFN maintenance treatment after HDT and ASCT in responsive patients demonstrates a significant prolongation of OS and PFS in the IFN-treated group. Furthermore, in the subgroup analysis, this difference was only detected in the PR patients, while no significant effect was seen in the CR patients. This pattern of response is consistent with some of the previous studies of ␣-IFN treatment after conventional chemotherapy, where ␣-IFN has induced a prolongation of either both OS and PFS 8, 16, 17 or of PFS only, 9,10,18 but
Bone Marrow Transplantation stands in contrast to other studies where no effect at all has been documented. 7, 19, 20 In the only randomized study of ␣-IFN maintenance treatment post-ASCT, 15 an early analysis at 4 years after transplantation demonstrated that ␣-IFN treatment was associated with a significant advantage in OS in all patients, and a significantly better PFS for the patients who achieved CR after transplantation, but not for those in PR. These differences, however, disappeared with time, and at 77 months post-ASCT no significant differences could be seen. Thus, no previous study has demonstrated the finding of the present study, ie, an effect most strongly pronounced in patients who did not achieve CR.
Concerning study design, only patients who were evaluable and responsive to HDT were included since it is reasonable to believe that the effect of ␣-IFN is very limited in unresponsive patients. Since the registry con-Bone Marrow Transplantation tains no information on time point for initiation or duration of IFN treatment, the inclusion point 6 months post-ASCT was chosen because we estimated by this time ␣-IFN treatment would be started for all patients in this group. Patients with poor graft performance were excluded from the study, because this would be a bias for not giving ␣-IFN therapy. These factors, in addition to the statistical correction methods, were applied in order to make the treatment and control groups as comparable as possible.
In the present study, the median OS from transplantation was 2.5 years longer in the IFN treatment group compared with the no-IFN group. Although this difference is highly statistically significant in the corrected survival analysis, it is probably not solely due to the effect of interferon. There is an overrepresentation of 'good' prognostic factors in the IFN group, and although these differences are statistically corrected for, the correction affects only the P value, but not the actual shape of or difference between the survival curves. In the Royal Marsden Hospital randomized study, where the treatment and control groups were well matched, the difference in median OS was about 1.5 years in favor of the IFNtreated group, and it is likely that this is more representative of the IFN effect than is the present retrospective study. 15 This is of clinical significance to the individual patient, and it is likely that this prolongation of survival outweighs possible differences in quality-of-life, due to adverse effects of interferon treatment. [21] [22] [23] Large randomized trials are warranted to identify the role of postautotransplant IFN maintenance treatment, and such intergroup studies are in progress in the United States.
